dm+d

Unassigned

New Medicines

Ontinua ER Multiple sclerosis (MS) - treatment of spasticity

Information

Ontinua ER
New molecular entity
Osmotica
Osmotica

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials

Category

GABA B receptor agonist
UK prevalence of MS is 100-180 per 100,000 people. 60% may have spasticity problems.
Multiple sclerosis (MS) - treatment of spasticity
Oral